Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Absci Corp (ABSI)

Absci Corp (ABSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 535,324
  • Shares Outstanding, K 150,372
  • Annual Sales, $ 4,530 K
  • Annual Income, $ -103,110 K
  • EBIT $ -107 M
  • EBITDA $ -94 M
  • 60-Month Beta 2.13
  • Price/Sales 116.74
  • Price/Cash Flow N/A
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 72.59% (-18.54%)
  • Historical Volatility 108.21%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 260.89% on 03/07/25
  • IV Low 72.59% on 12/24/25
  • Expected Move (DTE 22) 0.70 (19.58%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 294
  • Volume Avg (30-Day) 1,374
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 40,343
  • Open Int (30-Day) 38,463
  • Expected Range 2.86 to 4.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 5
  • High Estimate -0.11
  • Low Estimate -0.22
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +32.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.90 +22.76%
on 11/25/25
4.06 -12.32%
on 12/10/25
+0.60 (+20.27%)
since 11/24/25
3-Month
2.48 +43.55%
on 09/25/25
5.23 -31.91%
on 10/16/25
+1.07 (+42.97%)
since 09/24/25
52-Week
2.01 +77.11%
on 04/04/25
6.33 -43.76%
on 02/18/25
+0.55 (+18.27%)
since 12/24/24

Most Recent Stories

More News
Medical Breakthroughs: 5 AI Innovators Redefining What's Possible

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61...

CBLL : 21.42 (+0.61%)
ONMD : 1.3300 (+3.10%)
VPT.VN : 0.120 (-4.00%)
LNAI : 0.9860 (-0.62%)
ABSI : 3.56 (+1.14%)
VPTDF : 0.0918 (+1.21%)
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference

VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today...

ABSI : 3.56 (+1.14%)
Financial Pressure Turns Healthcare AI From Pilots Into Profits

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures...

VPT.VN : 0.120 (-4.00%)
CCLD : 3.09 (-1.28%)
ABSI : 3.56 (+1.14%)
LNAI : 0.9860 (-0.62%)
CAI : 28.24 (+0.86%)
VPTDF : 0.0918 (+1.21%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 0.9700 (+1.68%)
SANA : 4.53 (unch)
ABSI : 3.56 (+1.14%)
RXRX : 4.40 (+0.92%)
TEM : 64.26 (-0.71%)
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201â„¢ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth  ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular...

ABSI : 3.56 (+1.14%)
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research

Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease Donovan to share his personal journey at Absci’s...

ABSI : 3.56 (+1.14%)
Absci Announces First Participants Dosed in Phase 1/2a HEADLINEâ„¢ Trial of AI-Designed Antibody ABS-201â„¢ for Androgenetic Alopecia

Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational...

ABSI : 3.56 (+1.14%)
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December...

ABSI : 3.56 (+1.14%)
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the...

ABSI : 3.56 (+1.14%)
Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced...

ABSI : 3.56 (+1.14%)

Business Summary

Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 3.70
2nd Resistance Point 3.65
1st Resistance Point 3.60
Last Price 3.56
1st Support Level 3.51
2nd Support Level 3.46
3rd Support Level 3.42

See More

52-Week High 6.33
Fibonacci 61.8% 4.68
Fibonacci 50% 4.17
Fibonacci 38.2% 3.66
Last Price 3.56
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar